Does Rallies show 13F holders for BNTC?

Yes. Rallies tracks hedge fund and 13F ownership data for BNTC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BNTC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BNTC. It does not provide personalized investment advice.

BNTC (Benitec Biopharma Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Benitec Biopharma Inc. Common Stock (BNTC) is a publicly traded Healthcare sector company. As of May 21, 2026, BNTC trades at $10.99 with a market cap of $374.12M and a P/E ratio of -10.37. BNTC moved +2.99% today. Year to date, BNTC is -7.57%; over the trailing twelve months it is -21.11%. Its 52-week range spans $8.49 to $17.15. Analyst consensus is strong buy with an average price target of $25.00. Rallies surfaces BNTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BNTC stock?

Hedge funds tracked by Rallies that own BNTC include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Benitec Biopharma Inc. Common Stock.

BNTC Key Metrics

Key financial metrics for BNTC
Metric	Value
Price	$10.99
Market Cap	$374.12M
P/E Ratio	-10.37
EPS	$-1.05
Dividend Yield	0.00%
52-Week High	$17.15
52-Week Low	$8.49
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-37.92M
Gross Margin	0.00%

Top Hedge Funds Holding BNTC

Exoduspoint Capital holds 77.91K shares of BNTC, changed +2.01% as of Sep 30, 2025.

Latest BNTC News

Benitec Biopharma Reports Durable BB-301 Responses at 24 Months and $184.8M Cash — May 14, 2026
Benitec Biopharma Reports $11.8M Q2 Loss, $189M Cash; BB-301 Shows 24-Month Gains — Feb 12, 2026

Recent BNTC Insider Trades

SUVRETTA CAPITAL MANAGEMENT, LLC bought 65.80K (~$884.35K) on Dec 29, 2025.
SUVRETTA CAPITAL MANAGEMENT, LLC bought 11.59K (~$155.73K) on Dec 29, 2025.
SUVRETTA CAPITAL MANAGEMENT, LLC bought 14.32K (~$187.59K) on Dec 26, 2025.

BNTC Analyst Consensus

4 analysts cover BNTC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.00.

Common questions about BNTC

Who owns BNTC stock?: Hedge funds tracked by Rallies that own BNTC include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Benitec Biopharma Inc. Common Stock.
Does Rallies show 13F holders for BNTC?: Yes. Rallies tracks hedge fund and 13F ownership data for BNTC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BNTC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BNTC. It does not provide personalized investment advice.